Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) released its quarterly earnings data on Monday. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24), Zacks reports.
Jasper Therapeutics Price Performance
Shares of NASDAQ:JSPR traded up $0.06 during trading on Friday, reaching $4.93. The company had a trading volume of 215,340 shares, compared to its average volume of 292,738. Jasper Therapeutics has a fifty-two week low of $3.13 and a fifty-two week high of $26.84. The stock's fifty day moving average price is $4.60 and its 200 day moving average price is $10.93. The firm has a market capitalization of $74.06 million, a price-to-earnings ratio of -1.04 and a beta of 2.74.
Analysts Set New Price Targets
A number of analysts have weighed in on the stock. Oppenheimer cut their price objective on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday. UBS Group reduced their price target on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has an average rating of "Buy" and a consensus price target of $62.22.
Get Our Latest Research Report on JSPR
Hedge Funds Weigh In On Jasper Therapeutics
An institutional investor recently raised its position in Jasper Therapeutics stock. Goldman Sachs Group Inc. lifted its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 233,758 shares of the company's stock after acquiring an additional 23,453 shares during the quarter. Goldman Sachs Group Inc. owned 1.56% of Jasper Therapeutics worth $1,005,000 at the end of the most recent quarter. 79.85% of the stock is owned by hedge funds and other institutional investors.
Jasper Therapeutics Company Profile
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Stories
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
